Geon Kook Lee
The Breast Cancer Research Foundation
Fusion geneCancerInternal medicineRadiologyPathologyOncologyImmunohistochemistryHazard ratioLung cancerChemotherapyCarcinomaLungMetastasisEpidermal growth factor receptorGefitinibAdenocarcinomaPhases of clinical researchCancer researchCarcinogenesisMedicineBiologyGastroenterology
124Publications
31H-index
2,392Citations
Publications 111
Newest
#1Sunhee Chang (Inje University)H-Index: 9
#2Hyo Sup Shim (Yonsei University)H-Index: 28
Last. Chang Hun Lee (PNU: Pusan National University)H-Index: 27
view all 10 authors...
Molecular biomarker testing is the standard of care for non-small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved ta...
Source
#1Wonyoung ChoiH-Index: 5
#2Seog-Yun ParkH-Index: 4
Last. Ji-Youn HanH-Index: 32
view all 7 authors...
Purpose Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non-small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation or gene amplification. Materials and methods Patients who participated in the screening of a phase II study of capmatinib for advanced NSCLC were enrolled in this study. MET gene copy number (GCN), protein expression, and METex14 were analyzed and the patients' cl...
Source
#1Mihong Choi (Catholic University of Korea)H-Index: 2
#2Heung Tae KimH-Index: 19
view all 10 authors...
Purpose Squamous cell carcinomas (SqCC) of the lung often express high levels of thymidylate synthase (TS), which is associated with primary resistance to pemetrexed. We explored the efficacy of pemetrexed in a selected population of patients with lung SqCC with low TS expression. Materials and methods In this single-arm phase II trial, we enrolled 32 previously-treated patients with advanced lung SqCC exhibiting low immunohistochemical staining for TS (i.e., in 10% or less of tumor cells). The ...
Source
#1Kieun Bae (Konkuk University)H-Index: 4
#2Jin Hee Kim (Cheongju University)H-Index: 3
Last. Kyong-Ah Yoon (Konkuk University)H-Index: 13
view all 12 authors...
BACKGROUND Recently, fusion variants of the breast cancer anti-oestrogen-resistance 4 (BCAR4) gene were recurrently discovered in lung adenocarcinoma from the genome-wide studies. However, the functional characterisation of BCAR4 fusion has not been investigated. METHODS Based on the analysis of RNA-sequencing data, we identified a fusion transcript of CD63-BCAR4 in a Korean patient with lung adenocarcinoma who did not harbour any known activating mutations in EGFR and KRAS genes. To investigate...
Source
#1Duk Hwan MoonH-Index: 5
#2Jin Ho ChoiH-Index: 1
Last. Jae Hyun JeonH-Index: 5
view all 7 authors...
Background This study assessed the prognostic significance of metastatic lymph node size (MLNS) and extranodal extension (EN) in patients with node-positive lung adenocarcinoma (ADC). Methods Prognostic factors influencing survival were analyzed, including age, sex, extent of operation, T- and N-stage, size of tumor, postoperative chemotherapy, presence of EN, and MLNS (>7.0 vs. ≤7.0 mm). Results Three hundred seventy-five patients met the inclusion criteria were enrolled (mean age: 59.8±10.5 ye...
Source
#1Young-Joo LeeH-Index: 46
Last. Jin Soo LeeH-Index: 27
view all 8 authors...
Abstract Background We aimed to evaluate whether intercalated combination of EGFR tyrosine kinase inhibitor gefitinib and chemotherapy improves survival outcomes in never smokers with advanced lung adenocarcinoma. Patients and Methods Never-smokers with chemo-naive stage IIIB/IV lung adenocarcinoma were randomly assigned to receive either gefitinib or placebo on days 5-18 of a 3-weekly cycle of pemetrexed and cisplatin. Chemotherapy was given up to 9 cycles, after which gefitinib or placebo was ...
Source
#1Jae-Won HyunH-Index: 1
#1Jae-Won HyunH-Index: 15
Last. Sung Uk Kwon (Inje University)H-Index: 5
view all 8 authors...
5 CitationsSource
#1Young-Joo LeeH-Index: 46
Last. Ji Youn HanH-Index: 21
view all 12 authors...
Abstract Objectives Accumulating evidence reveals the association between the risk of never-smoker lung cancer and family history of cancer. However, the clinicogenomic effect of family history of cancer in never-smoker lung cancer remains unknown. Material and methods We screened 3,241 lung cancer patients who (a) underwent curative resection at National Cancer Center (Goyang, Korea) between 2001–2014, and (b) completed a pre-designed interview about family/smoking history at the time of diagno...
2 CitationsSource
#1Myunghee Kang (Gachon University)H-Index: 5
#2Seung Yeon Ha (Gachon University)H-Index: 10
Last. Wan Seop Kim (Konkuk University)H-Index: 16
view all 17 authors...
Source
#1Duk Hwan MoonH-Index: 5
#2Jae Hyun JeonH-Index: 5
Last. Geon Kook LeeH-Index: 31
view all 8 authors...
Background The purpose of this study was to assess the clinicopathologic implications of intramural metastasis (IM) in patients with esophageal squamous cell carcinoma (ESCC). Methods We retrospectively analyzed 743 patients who underwent esophagectomy. Among these patients, IM was detected in 41 patients (5.5%). The clinicopathologic features of IM and its influence on postoperative recurrence were investigated. Results In total, 710 male patients and 33 female patients with a mean age of 64.4 ...
8 CitationsSource